EGFR and non-small cell lung carcinoma: In some cases, identification of genetic aberrations is a prerequisite for commencing treatment; for example, identification of EGFR-activating mutations in patients with non-small cell lung cancer is required prior to starting treatments with EGFR tyrosine kinase inhibitors [2].